mTORC通路激活与西罗莫司治疗原生肾脏抗磷脂综合征肾病:一例病例报告
本文报告一例原生肾脏活动性APS肾病患者,分子水平证实内皮mTORC激活,西罗莫司治疗重复肾活检显示抑制AKT/mTORC通路,肾功能及血管病变显著改善,药物耐受良好。该病例验证并扩展了肾移植受者的既往观察,支持mTORC激活作为疾病活动生物标志物和治疗靶点。
要点
- 原生肾脏APS肾病中存在内皮AKT/mTORC通路激活。
- 西罗莫司可抑制该通路并改善肾功能与血管病变。
- mTORC激活可能作为APS肾病活动性和治疗靶点。
核心结论
- 西罗莫司在原生肾脏APS肾病中抑制AKT/mTORC通路,与肾功能和血管病变显著改善相关。
研究设计与样本
- 病例报告:一例原生肾脏活动性APS肾病患者,接受西罗莫司治疗并重复肾活检。
主要发现
- 分子水平证实受损肾血管内皮存在mTORC激活。
- 重复肾活检显示西罗莫司成功抑制AKT/mTORC通路。
- 治疗与肾功能显著改善及血管病变改善相关。
- 整个随访期间药物耐受性良好。
临床怎么用
- 对原生肾脏APS肾病患者可考虑评估mTORC激活状态。
- 西罗莫司可能作为难治性APS肾病的靶向治疗选择。
局限性
- 单例病例报告,证据级别有限,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite optimal anticoagulation and blood pressure control, patients with antiphospholipid syndrome (APS) nephropathy frequently progress to kidney failure, and recurrence after transplantation is common. The mTORC (mechanistic target of rapamycin complex) pathway was recently identified as a potential intermediate and a therapeutic target in vascular lesions associated with APS nephropathy. However, these results were derived from the retrospective analysis of a small cohort of patients receiving sirolimus after kidney transplantation. Therefore, they warranted external validation and the demonstration of the potential benefit of sirolimus in native kidney APS nephropathy. We report a patient with active APS nephropathy lesions occurring on native kidneys, in which endothelial mTORC activation was substantiated at the molecular level. Treatment with sirolimus was shown on a repeat kidney biopsy to successfully inhibit the AKT/mTORC pathway and was associated with significant improvement in kidney function and lesions of vasculopathy. Drug tolerance was excellent during the entire follow-up. This case validates and extends previous observations in kidney transplant recipients and demonstrates that endothelial activation of the AKT/mTORC pathway occurs in the damaged renal vasculature of native kidneys in APS nephropathy. These findings further support the potential of precision medicine and the use of mTORC activation as a biomarker of disease activity and as therapeutic target in patients with APS nephropathy.
引用
- Dufour I, Venot Q, Aydin S, et al. mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report. Am J Kidney Dis. 2019. PMID: 31810732. doi:10.1053/j.ajkd.2019.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。